PRIME: How The EU Scheme Is Delivering On Promise Of Faster Drug Approvals

Nineteen new products that were developed under PRIME, the European Medicines Agency’s priority medicines scheme, are now approved for use in the EU. Pink Sheet analysis finds that many were reviewed much faster than they would have been under standard review timelines.